Hematuria Treatment Market Research Report -Forecast to 2027

Hematuria Treatment Market Share, Insights And Growth Analysis By Type (Gross, Microscopic And Others), By Causes (Kidney Stones, Prostate Cancer, And Urethritis), By Treatment (Drugs And Therapies), By End-Users (Hospitals, Clinics, And Labs) - Forecast Till 2027

ID: MRFR/MED/1200-HCR | | Region: Global | 85 pages

Hematuria Treatment Market Scenario


The Hematuria Treatment Market is expected to grow significantly during the forecast period (2016–2022).


The presence of blood in the urine is the medical condition termed as Hematuria. Kidney stones, Urinary Tract Infection (UTI), and inherited diseases are some of the causes of hematuria. The disease is a serious issue as normal urine does not contain red blood cells (RBC). According to the American Urological Association (AUA), microscopic hematuria is defined as three or more RBC’s per high-power field on the microscopic assessment of urinary residue after two to three times of urine analysis.


Major factors such as rising frequency rate in numerous types of hematuria and increasing awareness boost the market rate. Furthermore, the rise in technology such as point-of-care drug delivery systems and focus on delivering good quality of life are some of the factors contributing to the growth of the market. However, increase in healthcare expenditure, complications in the treatment, strict rules and regulations for approvals, and the high cost of product developments are some of the restraining factors that hamper the market negatively.


Segmentation


The Hematuria Treatment Market has been segmented on the basis of type, causes, treatment, and end-user.


On the basis of type, the hematuria treatment market has been classified as gross or macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria.


On the basis of causes, the hematuria treatment market has been classified as kidney stones, urinary tract infections (UTI), urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, and menstruation.


On the basis of treatment, the hematuria treatment market has been classified as drugs, therapeutics, and others.


On the basis of end-user, the hematuria treatment market has been classified as hospitals, clinics, labs, and others.


On the basis of region, the hematuria treatment market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.


The European hematuria treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The hematuria treatment market information in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hematuria treatment market information in the Middle East and Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Hematuria Treatment Market  Share, by Region, 2017 (%)


Hematuria Treatment Market Share


Source: MRFR Analysis


Geographically, North America accounts to hold the largest market share due to the early adoption of advanced medical technologies and continuous development by companies operating in the hematuria treatment market.


The European market is likely to be the second largest owing to the increase in the prevalence of urinary tract infections (UTI) associated with women. The market growth in this region can be attributed to government funding and support from the healthcare sector coupled with increasing research and development.


The market share in the Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities, growing demand for advanced technology, better adoption rate, increasing government initiatives, and rising healthcare expenditure.


The market in the Middle East and Africa is expected to account for the smallest share of the Hematuria Treatment Market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.


Key Players


Some of the key players in the Hematuria Treatment Market are AstraZeneca Plc. Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Novartis International AG, Pfizer, Inc., Sun Pharmaceutical Industries Limited, The Medicines Company, and others.                


Hematuria Treatment Market, by Type



  • Gross or macroscopic hematuria

  • Microscopic hematuria

  • Idiopathic hematuria

  • Jogger’s hematuria


Hematuria Treatment Market, by Causes



  • Kidney stones

  • Urinary Tract Infections (UTI)

  • Urethritis

  • Blood cancer

  • Bladder stones

  • Prostate cancer

  • Cystitis

  • Trauma

  • Vigorous exercise

  • Polycystic kidney disease

  • Endometriosis

  • Menstruation


Hematuria Treatment Market, by Treatment



  • Drugs

  • Therapeutics

  • Others


Hematuria Treatment Market, by End-Users



  • Hospitals

  • Clinics

  • Laboratories

  • Research centers

  • Others


Hematuria Treatment Market, by Region



  • Americas

  • North America

  • US

  • Canada

  • South America

  • Europe

  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe

  • Asia-Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific

  • Middle East & Africa

  • Middle East

  • Africa


Intended Audience



  • Hematuria equipment manufacturers & suppliers

  • Hematuria treatment products manufacturers & suppliers

  • Pharmaceutical and biotechnology companies

  • Hospitals and diagnostic centers

  • Medical device companies

  • Academic research institutes



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2020-2027: Substantial CAGR
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Causes, Treatment, and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   AstraZeneca Plc. Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Novartis International AG, Pfizer, Inc., Sun Pharmaceutical Industries Limited, The Medicines Company, and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Rising frequency rate in numerous types of hematuria
  • Increasing awareness


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The outlook of the hematuria treatment market looks very promising.

    Huge investments for the development of products related to hematuria treatment, rising prevalence of hematuria and increasing awareness, evolving technology such as point-of-care drug delivery systems and focus on delivering best possible care, and rise in the global economy that is widening the access to the quality care are the major tailwinds pushing the growth of the hematuria treatment market.

    North America holds the largest share in the hematuria treatment market, followed by Europe and the Asia Pacific, respectively.

    Bristol-Myers Squibb, AstraZeneca Plc., F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., GlaxoSmithKline Inc., Merck & Co., Pfizer, Inc., Novartis International AG, Sun Pharmaceutical Industries Limited, and The Medicines Company, are some of the major players operating in the hematuria treatment market.

    Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global hematuria treatment market adopt to gain a larger competitive advantage.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Hematuria Treatment Market Information, by Type

    6.1 Introduction

    6.2 Gross or Macroscopic Hematuria

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3 Microscopic hematuria

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4 Idiopathic hematuria

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.5 Jogger’s hematuria

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 7. Global Hematuria Treatment Market Information, by Causes

    7.1 Introduction

    7.2 Kidney stones

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3 Urinary tract infections (UTI)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4 Urethritis

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.5 Blood cancer

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.6 Bladder stones

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.7 Prostate cancer

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.8 Cystitis

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.9 Trauma

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.10 Vigorous exercise

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.11 Polycystic kidney disease

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.12 Endometriosis

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.13 Menstruation

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 8. Global Hematuria Treatment Market Information, by Treatment

    8.1 Introduction

    8.2 Drugs

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3 Therapeutics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.4 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 9. Global Hematuria Treatment Market Information, by End-Users

    8.1 Introduction

    8.2 Hospitals

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3 Clinics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.4 Laboratories

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.5 Research centers

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.6 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 10. Global Hematuria Treatment Market Information, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia-Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 South Korea

    10.4.6 Rest of Asia-Pacific

    10.5 Middle East & Africa

    10.5.1 Middle East

    10.5.2 Africa

    Chapter 11. Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    Chapter 12. Company Profiles

    12.1 AstraZeneca Plc.

    12.1.1 Company Overview

    12.1.2 Type Overview

    12.1.3 Financials Overview

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 Bristol-Myers Squibb

    12.2.1 Company Overview

    12.2.2 Type Overview

    12.2.3 Financials Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 F. Hoffmann-La Roche Ltd

    12.3.1 Company Overview

    12.3.2 Type Overview

    12.3.3 Financials Overview

    12.3.4 Key Developments

    12.3.5 SWOT Analysis

    12.4 GlaxoSmithKline Inc.

    12.4.1 Company Overview

    12.4.2 Type Overview

    12.4.3 Financials Overview

    12.4.4 Key Developments

    12.4.5 SWOT Analysis

    12.5 Janssen Pharmaceuticals, Inc.

    12.5.1 Company Overview

    12.5.2 Type Overview

    12.5.3 Financials Overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 Merck & Co.

    12.6.1 Company Overview

    12.6.2 Type Overview

    12.6.3 Financials Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.7 Novartis International AG

    12.7.1 Company Overview

    12.7.2 Type Overview

    12.7.3 Financials Overview

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Pfizer, Inc.

    12.8.1 Company Overview

    12.8.2 Type Overview

    12.8.3 Financials Overview

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Sun Pharmaceutical Industries Limited

    12.9.1 Company Overview

    12.9.2 Type Overview

    12.9.3 Financials Overview

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.10 The Medicines Company

    12.10.1 Company Overview

    12.10.2 Type Overview

    12.10.3 Financials Overview

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.11 Others


    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s Viewpoint

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Predictions for the Biosurgery Industry

    Chapter 14. Appendix

    LIST OF TABLES

    Table 1 Global Hematuria Treatment Market Information Synopsis, 2020-2027

    Table 2 Global Hematuria Treatment Market Information Estimates and Forecast, 2020-2027 (USD Million)

    Table 3 Global Hematuria Treatment Market Information, by Region, 2020-2027 (USD Million)

    Table 4 Global Hematuria Treatment Market Information, by Type, 2020-2027 (USD Million)

    Table 5 Global Hematuria Treatment Market Information, by Causes, 2020-2027 (USD Million)

    Table 6 Global Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD Million)

    Table 7 North America: Hematuria Treatment Market Information, by Type, 2020-2027 (USD

    Million)

    Table 8 North America: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD

    Million)

    Table 9 North America: Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD

    Million)

    Table 10 US: Hematuria Treatment Market Information, by Type, 2020-2027 (USD Million)

    Table 11 US: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD Million)

    Table 12 US: Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD Million)

    Table 13 Canada: Hematuria Treatment Market Information, by Type, 2020-2027 (USD Million)

    Table 14 Canada: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD Million)

    Table 15 Canada: Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD

    Million)

    Table 16 South America: Hematuria Treatment Market Information, by Type, 2020-2027 (USD

    Million)

    Table 17 South America: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD

    Million)

    Table 18 South America: Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD

    Million)

    Table 19 Europe: Hematuria Treatment Market Information, by Type, 2020-2027 (USD Million)

    Table 20 Europe: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD Million)

    Table 21 Europe: Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD Million)

    Table 22 Western Europe: Hematuria Treatment Market Information, by Type, 2020-2027 (USD

    Million)

    Table 23 Western Europe: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD

    Million)

    Table 24 Western Europe: Hematuria Treatment Market Information, by Treatment, 2020-2027

    (USD Million)

    Table 25 Eastern Europe: Hematuria Treatment Market Information, by Type, 2020-2027 (USD

    Million)

    Table 26 Eastern Europe: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD

    Million)

    Table 27 Eastern Europe: Hematuria Treatment Market Information, by Treatment, 2020-2027

    (USD Million)

    Table 28 Asia-Pacific: Hematuria Treatment Market Information, by Type, 2020-2027 (USD

    Million)

    Table 29 Asia-Pacific: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD

    Million)

    Table 30 Asia-Pacific: Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD

    Million)

    Table 31 Middle East & Africa: Hematuria Treatment Market Information, by Type, 2020-2027

    (USD Million)

    Table 32 Middle East & Africa: Hematuria Treatment Market Information, by Causes, 2020-2027

    (USD Million)

    Table 33 Middle East & Africa: Hematuria Treatment Market Information, by Treatment, 2020-2027

    (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Hematuria Treatment Market Information

    Figure 3 Segmentation Market Dynamics for Global Hematuria Treatment Market Information

    Figure 4 Global Hematuria Treatment Market Information Share, by Type, 2020

    Figure 5 Global Hematuria Treatment Market Information Share, by Causes, 2020

    Figure 6 Global Hematuria Treatment Market Information Share, by Treatment, 2020

    Figure 7 Global Hematuria Treatment Market Information Share, by Region, 2020

    Figure 8 North America: Hematuria Treatment Market Information Share, by Country, 2020

    Figure 9 Europe: Hematuria Treatment Market Information Share, by Country, 2020

    Figure 10 Asia-Pacific: Hematuria Treatment Market Information Share, by Country, 2020

    Figure 11 Middle East & Africa: Hematuria Treatment Market Information Share, by Country, 2020

    Figure 12 Global Hematuria Treatment Market Information: Company Share Analysis, 2020 (%)

    Figure 13 AstraZeneca plc.: Key Financials

    Figure 14 AstraZeneca plc.: Segmental Revenue

    Figure 15 AstraZeneca plc.: Geographical Revenue

    Figure 16 Bristol-Myers Squibb: Key Financials

    Figure 17 Bristol-Myers Squibb: Segmental Revenue

    Figure 18 Bristol-Myers Squibb: Geographical Revenue

    Figure 19 F. Hoffmann-La Roche Ltd: Key Financials

    Figure 20 F. Hoffmann-La Roche Ltd: Segmental Revenue

    Figure 21 F. Hoffmann-La Roche Ltd: Geographical Revenue

    Figure 22 GlaxoSmithKline Inc.: Key Financials

    Figure 23 GlaxoSmithKline Inc.: Segmental Revenue

    Figure 24 GlaxoSmithKline Inc.: Geographical Revenue

    Figure 25 Janssen Pharmaceuticals, Inc.: Key Financials

    Figure 26 Janssen Pharmaceuticals, Inc.: Segmental Revenue

    Figure 27 Janssen Pharmaceuticals, Inc.: Geographical Revenue

    Figure 28 Merck & Co.: Key Financials

    Figure 29 Merck & Co.: Segmental Revenue

    Figure 30 Merck & Co.: Geographical Revenue

    Figure 31 Novartis International AG: Key Financials

    Figure 32 Novartis International AG: Segmental Revenue

    Figure 33 Novartis International AG: Geographical Revenue

    Figure 34 Pfizer, Inc.: Key Financials

    Figure 35 Pfizer, Inc.: Segmental Revenue

    Figure 36 Pfizer, Inc.: Geographical Revenue

    Figure 37 Sun Pharmaceutical Industries Limited: Key Financials

    Figure 38 Sun Pharmaceutical Industries Limited: Segmental Revenue

    Figure 39 Sun Pharmaceutical Industries Limited: Geographical Revenue

    Figure 40 The Medicines Company: Key Financials

    Figure 41 The Medicines Company: Segmental Revenue

    Figure 42 The Medicines Company: Geographical Revenue

    Figure 43 Others: Key Financials

    Figure 44 Others: Segmental Revenue

    Figure 45 Others: Geographical Revenue